Although results were less dramatic for PCDHA1 and signature 2, we still observed a ~ 25% elevated mortality at 5 years for these two patient groups with bladder urothelial carcinoma (P = 0.040; Fig. 4). Here, PCDHA1 is linked to bladder transitional cell carcinoma.